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Rheumatoid  arthritis  (RA) mainly  affects  various  joints  of the body,  including  the  temporomandibular
joint (TMJ),  and  it involves  an inﬁltration  of autoantibodies  and  inﬂammatory  leukocytes  into  articular
tissues  and  the  synovium.  Initially,  the  synovial  lining  tissue  becomes  engaged  with  several  kinds  of
inﬁltrating  cells,  including  osteoclasts,  macrophages,  lymphocytes,  and plasma  cells.  Eventually,  bone
degradation  occurs.  In  order to elucidate  the  best  therapy  for RA,  a comprehensive  study  of  RA pathogen-
esis  needs  to  be  completed.  In this  article,  we  discuss  a  Fas-deﬁcient  condition  which  develops  into  RA,heumatoid arthritis
steoclast
as
1P1
F-B
with  an  emphasis  on  the  role  of  sphingosine  1-phosphate  (S1P)/S1P  receptor  1 signaling  which  induces
the  migration  of osteoclast  precursor  cells.  We  describe  that Fas/S1P1 signaling  via NF-B  activation  in
osteoclasts  is  a  key  factor in  TMJ-RA  severity  and  we  discuss  a strategy  for blocking  nuclear  translocation
of  the  p50  NF-B  subunit  as  a potential  therapy  for  attenuating  osteoclastogenesis.
© 2018  The  Authors.  Published  by Elsevier  Ltd on  behalf  of  The  Japanese  Association  for  Dental
Science.  This  is  an  open  access  article  under  the CC BY-NC-ND  license  (http://creativecommons.org/. Introduction
Rheumatoid arthritis (RA) develops when the synovial lining
f joints in the body are inﬁltrated by leukocytes, plasma cells,
ymphocytes, endothelial cells, and activated macrophages that
ediate induction of a chronic inﬂammatory state (Fig. 1) [1,2].
one erosions often accompany the development of an inﬂamma-
ory state in many rheumatic diseases and these destructive bone
esions develop when a break in cortical bone has occurred. Loss of
djacent trabecular and cortical bone structures proximal to a bone
esion generally occur due to osteoclastic bone resorption, a reduc-
ion in articular cartilage, and bone marrow edema [3,4]. The latter
an be detected with magnetic resonance imaging (MRI) [5,6].
In RA, the size and number of erosions that are present in
ffected joints may  be an indicator of the extent of damage that
as occurred. Bone erosions represent the contribution of the bone
arrow compartment to the destruction of bone and the promotion
f cytokines involved in pro-inﬂammation [7,8]. Osteoclasts are
ultinucleated myeloid lineage cells that are able to resorb bone,
nd these cells are essential for the remodeling and regeneration of
one. In degenerative diseases such as arthritis, osteoporosis, and
∗ Corresponding author.
E-mail address: tizawa@tokushima-u.ac.jp (T. Izawa).
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882-7616/© 2018 The Authors. Published by Elsevier Ltd on behalf of The Japanese Ass
icense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).licenses/by-nc-nd/4.0/).
cancer bone metastasis, the presence of an excessive number of
osteoclasts has been found to contribute to bone destruction [9].
Receptor activator of NF-B ligand (RANKL) and macrophage
colony-stimulating factor (M-CSF) stimulate the generation of
osteoclast cells [10–13]. In response to sphingosine 1-phosphate
(S1P) signaling, osteoclasts then attach to regions of bone under-
going resorption [14]. In RA when S1P is expressed at higher levels,
sphingosine kinase (Sphk) 1 is also present at higher levels and this
leads to resistance to Fas-mediated death signaling (Fig. 2) [15,16].
The activity and number of osteoclasts are modulated by rates of
cell death and cell differentiation [17].
Communication between osteoclasts and osteoblasts or T cells
is also mediated by RANKL and S1P receptor 1 (S1P1), and this
signaling promotes cell regulation, proliferation, migration, apo-
ptosis, expression of inﬂammatory genes [18–20], chemotaxis [21],
and differentiation [22,23]. Events downstream of RANKL binding
to osteoclasts involves the activation of various signaling path-
ways, including nuclear factor of activated T cells cytoplasmic 1
(NFATc1), Akt/PKB, NF-B, JNK, p38, and ERK, to induce the differ-
entiation, activity, and survival of osteoclasts [14,24]. In addition,
RANKL binding of osteoclast progenitor cells leads to upregula-
tion of Fas expression via NF-B, thereby resulting in osteoclast
cells being targets of Fas-stimulated apoptosis [25]. To promote cell
death, Fas-stimulated apoptosis in osteoclasts involving the release
ociation for Dental Science. This is an open access article under the CC BY-NC-ND
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fig. 1. Bone destruction associated with TMJ-RA. RANKL is produced by T cells an
he  local destruction of cartilage and eventually severe subchondral trabecular bone
ells  (monocytes) concomitant with a decrease in the recruitment and differentiati
f cytochrome c from mitochondria and activation of both caspase
 and caspase 9 [17].
To date, the predominant strategies for decreasing bone
esorption include the addition of estrogen, tamoxifen, or cer-
ain bisphosphonates to accelerate the death rate of osteoclasts
r decrease osteoclast formation [17,26–30]. In this review, we
iscuss our ﬁndings that osteoclast activity-dependent Fas/S1P1
ignaling via activation of NF-B mediates the development of RA
nd bone resorption in the TMJ. In addition, a prospective therapeu-
ic intervention involving administration of SN50 to block signaling
y p50 NF-B to attenuate osteoclastogenesis in the pathogene-
is of temporomandibular joint rheumatoid arthritis (TMJ-RA) is
iscussed.
. TMJ-RA
The TMJ  is needed for sliding and hinge movements of the
aw. Consequently, it is the most frequently used joint in the body
31]. The TMJ  is composed of an articular disc and the mandibular
ondyle which provide upper and lower articular cavities between
he condyle and the glenoid fossa [32]. Unlike other synovial joints,
he condyle of the mandible of the TMJ  produces less type I collagen
33], its superﬁcial layer does not produce type II collagen, and its
rticular surfaces consist of ﬁbrous tissue rather than hyaline carti-
age [34]. In addition, mandibular condyle cartilage originates from
ranial neural crest cells and is considered a secondary cartilage of
he chondroskeleton [35].
Clinically, the TMJ  is involved in 4–80% of RA cases [36–38].
his wide range is due on the different examinations performed,
he different selection of the patient populations and age distribu-
ion, the duration of the RA occurs, the different diagnostic criteria
or classifying joint involvement, and the imaging techniques usedmed synovium (synovitis) tissue. The presence of this cytokine in the TMJ leads to
as a result of the recruitment and enhanced differentiation of osteoclast progenitor
steoblast progenitor cells and MSCs.
[5,37–43]. However, more than 50% of patients with RA complaints
about TMJ  discomfort [36,44,45].
Manifestation of RA in the TMJ  can include swelling, pain,
impaired movement, and crepitation. These characteristics are sim-
ilar to the manifestations of RA in other joints, and these symptoms
usually correlate well with radiographic change observed in joints.
Speciﬁcally in the TMJ, radiographic changes can include erosion,
the presence of a subcortical cyst, and a gradual decrease in joint
space due to granulation, deossiﬁcation, pencil head, or spiked
deformity of the condylar head [41,44].
Several studies were found in TMJ-RA. Proteoglycan-induced
arthritis mice showed a degradation of cartilage matrix in TMJ
due to the effects of the cytokines from the inﬂamed joints [46].
The ratio of RANKL and OPG was signiﬁcantly increased in TMJ  of
collagen-induced acetate rats [47]. The pathway of TMJ  involve-
ment in human RA was  found to be the same as in other joints based
on the analysis of histological ﬁndings [48]. However, it should be
emphasized that due to the originates difference of the cartilage of
TMJ  and other joints [35], the pathogenesis of RA in TMJ may  differ
from the other joints.
Therefore, the histomorphology and the comprehensive analy-
sis of TMJ-RA pathogenesis need to be completed although clinical
ﬁndings in TMJ-RA are similar to RA in other joints [41]. Especially
for the dentist, the difﬁculties associated with diagnosing TMJ-RA
patients [49] posing challenges to diagnose and recover the effects
of TMJ-RA.
3. Fas-deﬁciency in RA pathogenesisFas antigen is expressed in various tissues, including the thymus.
Fas antigen also shares structural homology with many cell-surface
receptors (e.g., tumor necrosis factor (TNF) receptors) and has been
shown to mediate apoptosis [50]. In human RA, FLICE-inhibitory
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Fig. 2. A proposed model of the mechanism and action by which crosstalk between the Fas and S1P/S1P signaling pathways regulate osteoclastogenesis. Upon binding
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urvival and massive bone destruction.
rotein (FLIP) an antiapoptotic protein, has been detected in syn-
vial tissues and ﬁbroblast-like synoviocytes (FLS) culture. It has
een reported that FLS of RA is sensitized to promote Fas mediated-
poptosis by the down-regulation of FLIP [51].
In mice, the Fas antigen gene maps to chromosome 19 and mice
hat carry a lymphoproliferation mutation (MRL/lpr mice) have
een found to have defects in the Fas antigen gene [52,53]. An
berrant transcription factor in MRL/lpr mice causes premature ter-
ination of Fas transcription, and this results in aberrant splicing of
as mRNA (Fig. 2) [54]. The clinical symptoms exhibited by MRL/lpr
ice include hypergammablobulinaemia, production of anti-DNA
ntibodies, rheumatoid factor (RF), arthritis, and glomerulonephri-
is. Moreover, the latter closely resembles human autoimmune
ystemic lupus erythematosus (SLE) [55].
MRL/lpr mice are suitable as a model to study an immune
omplex disease, to determine the etiology, and to evaluate the
herapies. Several studies were done using MRL/lpr mice, such
s the effect of the radiation therapy to ameliorate the autoim-
une disease [56], the therapeutic effects of Artemisinin analog
M934 to ameliorate lupus syndromes [57], allergic inﬂammation
n blepharitis [58], the analysis pathogenesis of Graft-versus-host
isease (GVHD)-like wasting syndrome by defects in Fas-mediated
ymphocyte apoptosis [59], and histopathological analysis of spon-
aneous arthritis [60,61].
The pathogenesis of RA in MRL/lpr mice particularly involves
nteractions between osteoclast cells and immune cells (e.g., acti-1
5 subunits of NF-B are able to translocate to the nucleus, bind DNA, and activate
last progenitor cells, while defects in Fas mitigate apoptosis to promote osteoclast
vated dendritic cells (DCs) with peripheral T cells) via RANKL
activation. Thus, a possible therapeutic treatment for lymphoprolif-
erative and autoimmune arthritis has been tested in MRL/lpr mice
with induction of Fas-independent apoptosis of CD4+ T cells via
TRAIL/TRAIL-R2 which was  achieved by performing multiple trans-
fers of activated and Fas-deﬁcient DCs [62,63]. It has been reported
that osteoprotegerin (OPG) induces apoptosis in osteoclast and
osteoclast precursor via Fas/FasL pathway. OPG has been shown
to trigger the increase of Bax/Bcl-2 ratio and the level of activated
cleaved-caspase 9 and caspase 3 in dose-dependent manner [64].
When staining for tartrate-resistant acid phosphatase (TRAP)
was performed in long bones and the TMJs of MRL/lpr mice and
control mice, the former contained a greater number of osteoclasts.
This observation suggests that mutation of Fas leads to prolonged
survival of osteoclasts (Fig. 2) [17,65]. Correspondingly, defects in
Fas have been associated with a greater number of osteoclasts and
subsequent reductions in bone mineral density, bone volume, and
trabecular thickness [17].
4. The role of S1P/S1P1 signaling in osteoclasts under RA
conditionsS1P, a cell-derived lysophospholipid growth factor [66], is the
ﬁnal metabolite of the sphingolipid pathway and it is generated
from Sphk and S1P lyase [67]. S1P binds G protein-coupled recep-
tors (GPCRs) at the cell surface, particularly the S1P1–5 receptors
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Fig. 3. The molecular mechanism of S1P signaling via its receptors. Extracellular molecules, including pro-inﬂammatory cytokines, growth factors, and S1P itself, can
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athway, while S1P2 and S1P3 are linked to G12/13 and activate the Rho signaling p
Fig. 3) [68], to mediate a wide variety of essential cellular pro-
esses: cell differentiation, survival, proliferation, migration, and
nvasion, as well as angiogenesis and trafﬁcking of immune cells
69–72]. While S1P1–3 are widely expressed in various tissues,
xpression of S1P4 and S1P5 is restricted to immune cells and cells
f the central nervous system [73,74].
Potential roles for S1P in angiogenesis, cancer, and autoimmune
iseases such as RA have been reported [73]. In RA synoviocytes,
1P has been shown to enhance expression of prostaglandin E2
PGE2) and cyclooxygenase-2 (COX-2) in response to the pro-
nﬂammatory cytokines, TNF- and interleukin (IL)-1 [18]. These
ytokines production induce expression of matrix metallopro-
einases (MMPs) and activate osteoclasts, thereby resulting in bone
esorption and soft tissue damage [75]. Osteoclasts themselves also
xpress S1P, and this molecule stimulates the migration of both
steoblasts and mesenchymal stem cells (MSCs). Accordingly, S1P
hat derives from osteoclasts may  attract osteoblasts to areas of
one resorption as one of the ﬁrst steps in the process of replacing
one that is lost in a damaged area [76].
S1P signaling via S1P1 regulates T cell development and
nhances synoviocyte proliferation, inﬂammatory cytokine expres-
ion, and osteoclastogenesis in bone homeostasis [23,77–79].
eanwhile, expression of Sphk1 has been shown to be higher in
steoclasts that have cathepsin K deleted. These osteoblasts also
xhibited a higher RANKL/OPG ratio which corresponded with a
reater number of osteoclasts present [80].
Differentiation and maturation of osteoclasts require signaling
ia Sphk1/S1P/S1P3 as previously demonstrated in assays of Runx2
xpression and alkaline phosphatase activity [81]. Transforming
rowth factor (TGF)-/Smad3 signaling has also been shown to
ffect cartilage homeostasis by inﬂuencing S1P/S1P receptor sig-
aling and chondrocyte migration. Correspondingly, in mice with
mad3-deﬁcient chondrocytes, only the Sphk1/S1P/S1P3 signalingphk1. S1P is subsequently generated following phosphorylation of Sphk, and S1P
orylation events. S1P1 is linked to Gi and is a potent activator of the Rac signaling
ay.
axis was found to play an important role in degradation of the
mandibular condylar [82].
The S1P/S1P1 signaling axis controls the migration of osteoclast
precursor cells [21–23,83] from bone tissues into blood circula-
tion [21] and it may  also induce synovial hyperplasia in RA. RANKL
stimulation has been found to decrease expression of S1P1 in an
NF-B-dependent manner (Fig. 2) yet not in a NFATc1-dependent
manner [21,23]. Furthermore, RANKL expression during osteoclas-
togenesis that is induced by the Sphk1/S1P1 signaling axis is the
result of interactions between macrophages and bone marrow
derived stromal cells (BMSCs) [84].
However, in our recent study, only expression of Sphk1 and S1P1
in MRL/lpr mice increased in the mandibular condyle, and these
increases were accompanied by an increase in Rac1 activity (Fig. 3)
[21,65]. Correspondingly, treatment with a S1P1 agonist led to a
signiﬁcant reduction in inﬂammation and joint destruction, consis-
tent with the predicted actions of the agonist in retaining osteoclast
precursor cells [85]. Taken together, these ﬁndings suggest that tar-
geting the S1P/S1P1 signaling axis represents a potential treatment
for RA [18].
During the development of RA, expression of S1P and S1P1–5
by osteoclasts [65], osteoblasts [81], chondrocytes [82], and MSCs
[76,86] is considered to be essential for modulating cell migration,
cell survival, and cytokine or chemokine production during bone
formation (Fig. 1) [65,87]. Therefore, it will be important for future
studies to evaluate the role of the S1P/S1P receptor system among
the cell-cell interactions that mediate bone homeostasis in TMJ-RA
pathogenesis (Fig. 4).5. Role of the NF-B in osteoclasts
NF-B is an inducible transcription factor that binds a partic-
ular DNA sequence that is present in a large number of target
16 I.R. Hutami et al. / Japanese Dental Science Review 55 (2019) 12–19
Fig. 4. Schematic representation of the bone remodeling process. When Fas is defective, a greater amount of S1P is released by osteoclasts (grey arrows) and this leads
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ost  bone. An overall increase in the level of S1P then stimulates bone formation.
enes, especially genes that contribute to immune responses and
athogen defense. In autoimmune diseases, such as RA, NF-B has
n essential role in the differentiation, survival, activation, and
evelopment of osteoclasts [88–90].
Two important proteins in osteoclastogenesis are RANK and its
igand, RANKL (also referred to as TNFRSF11A and TRANCE, respec-
ively). In addition to activating mature osteoclasts, RANKL can
ombine with M-CSF to regulate osteoclast differentiation from
onocyte/macrophage precursor cells [14,89,91]. Numerous stud-
es have demonstrated that differentiation of osteoclast precursor
ells requires induction of NF-B activity by RANKL [88,92,93],
hile activation of macrophages and osteoclasts requires NF-B
ignaling as well [88,94].
Phosphorylation of the p50-Rel A dimer, the most common
orm of NF-B, leads to ubiquitination of IB proteins (Fig. 2).
oly-ubiquitination of IB proteins identiﬁes them for rapid degra-
ation by 26S proteasomes, thereby allowing NF-B dimers to
ndergo nuclear translocation and activate the transcription of var-
ous target genes [95]. However, prior to their degradation, the
hosphorylation of IB proteins by the IB kinase (IKK) complex
acilitates NF-B activation. The IKK complex consists of a reg-
latory component, IKK or NF-B essential modulator (NEMO),
nd catalytic subunits (IKK and IKK) [95–98]. In MRL/lpr mice,
hosphorylation of IB, an endogenous inhibitory molecule of
F-B activation and nuclear translocation of the p50 and p65 sub-
nits of NF-B, is signiﬁcantly enhanced compared with control
ice [65,99]. These results suggest that osteoclast activation which
ccurs with RA involves a role for the classical pathway of NF-B
ctivation (Fig. 2).
Correspondingly, in both in vivo and in vitro studies a cell-
ermeable peptide spanning a NEMO-binding domain has been
hown to inhibit osteoclastogenesis and activation of NF-B
nduced by RANKL [88]. Therefore, it is proposed that a potential
trategy for preventing osteoclastogenesis and effectively treating
he inﬂammation associated with bone resorption is to selectively
nhibit NF-B in osteoclasts [65,88].
. Blocking nuclear translocation of NF-B in osteoclasts as
herapeutic target of RA
Different strategies have been proposed and tested to inhibit
he activation or function of NF-B. One approach has employed
ecoy NF-B sites or their analogs to interfere with the binding
f NF-B to DNA [100]. However, such molecules are polar and
ather large, thereby potentially hindering their uptake and cellular
ioavailability [96]. Conversely, considering the large interaction
urface between NF-B and DNA, it may  be difﬁcult for non-polarulation of osteoblasts and the migration of osteoclast precursor cells occurs, and
cruit osteoblasts to bone resorption sites as an initial step in the process to replace
molecules that are small in size to speciﬁcally disrupt the binding of
NF-B to DNA [96]. A similar argument could be made for molecules
designed to inhibit NF-B protein dimerization [96,101].
Alternatively, it has been proposed that small peptides that can
readily cross the cell membrane could inhibit the activation of NF-
B by blocking translocation of the NF-B complex to the nucleus.
This approach was tested by generating a synthetic peptide that
contains the nuclear localization sequence of the p50 NF-B subunit
and a hydrophobic region to facilitate translocation across a cell
membrane. This peptide, named SN50, was  shown to competitively
inhibit the nuclear translocation of NF-B (Fig. 2) [96,100,102].
Moreover, both in vivo and in vitro, SN50 was  found to effectively
inhibit TNF- and lipopolysaccharide (LPS)-induced inﬂammatory
responses [102]. SN50 has also been shown to block the translo-
cation of many other transcriptional factors to the nucleus, and to
abrogate activation of caspase-3 [96,100,103,104]. In mice, admin-
istration of SN50 effectively suppressed NF-B activation that was
dependent on TNF-/JNK signaling [105], as well as MMP  produc-
tion in alveolar macrophages [106]. Furthermore, in resting normal
human peripheral blood derived T cells, the addition of SN50 abol-
ished osteoclast differentiation and induced apoptosis [107,108].
Based on the results presented here, blocking nuclear transloca-
tion of the p50 NF-B subunit appears to be an effective approach
for attenuating the number of osteoclasts present and reducing
expression of Sphk1 and S1P1. In particular, it has recently been
demonstrated that SN50 targeting of p50 NF-B translocation to
the nuclei of bone marrow macrophages (BMMs) in RA model of
MRL/lpr mice inhibits RANKL-induced osteoclastogenesis (Fig. 2)
[65].
Subchondral trabecular bone loss in the mandibular condyle
was also ameliorated, and this was accompanied by lower expres-
sion levels of the osteoclast marker, TRAP, as well as cathepsin
K, vascular endothelial growth factor (VEGF), MMP-9, and RANKL.
Moreover, treatment with SN50 increased expression of OPG and
reduced Sphk1 expression and S1P1 signaling [65]. Taken together,
these ﬁndings suggest that SN50 is an effective inhibitor of osteo-
clastogenesis and the preceding migration of osteoclast precursor
cells.
7. Conclusions
Osteoclcastogenesis is regulated by multiple signal transduc-
tion pathways. To maintain bone homeostasis, osteoclast cells must
achieve a balance regulation of formation, function, and trafﬁcking
of its precursors. Here, we proposed a model in which crosstalk
between Fas and S1P/S1P1 signaling occurs in osteoclast precursor
cells and it is dependent on activation of NF-B. Moreover, this sig-
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aling affects the migratory behavior of osteoclast precursor cells
hich is crucial for the pathogenesis of RA.
The TMJ  has special characteristics that distinguish it from other
oints in the human body. Correspondingly, disorders, symptoms,
nd disease distribution involving the TMJ  are unlike those of other
oint disorders. As a result, treatments speciﬁc for the TMJ  may be
eeded. However, given that the TMJ  is part of a dynamic tissue
hat undergoes constant remodeling as a result of bone resorp-
ion and bone formation processes that are mediated by osteoclasts
nd osteoblasts, respectively, continued efforts are needed to bet-
er understand RA pathogenesis for the identiﬁcation of effective
ew therapies.
uthor contributions
H. and T.I. conceived the idea.
I.H. and T.I made substantial contributions to the conception,
esigned, drafted, revised, and was involved in the ﬁnal approval
f the manuscript to be submitted for publication.
T.I. and E.T. reviewed the manuscript for important intellectual
ontent.
All authors approved the ﬁnal version to be published.
cknowledgments
This work was supported by the grants provided by JSPS KAK-
NHI (Grant Numbers. 25713063, 15K15757, 17K19758, 18H03011
o T.I.), The Ichiro Kanehara Foundation, Suzuken Memorial Foun-
ation, The Nakatomi Foundation, Smoking Research Foundation,
akeda Science Foundation, The Mochida Memorial Foundation for
edical and Pharmaceutical Research, Sumitomo Denko Founda-
ion, Mitsui Sumitomo Insurance Welfare Foundation to T.I., and
tsuka Toshimi Scholarship Foundation, Fujii-Otsuka Scholarship
o I.H.
onﬂicts of interest
The authors declare no conﬂict of interest.
eferences
[1] Karmakar S, Kay J, Gravallese EM.  Bone damage in rheumatoid arthritis: mech-
anistic insights and approaches to prevention. Rheum Dis Clin North Am
2010;36(2):385–404.
[2] Yang X, Chang Y, Wei  W.  Endothelial dysfunction and inﬂammation: immu-
nity in rheumatoid arthritis. Mediators Inﬂamm 2016;2016:1–9, 6813016.
[3] Jimenez-Boj E, Nobauer-Huhmann I, Hanslik-Schnabel B, Dorotka R,
Wanivenhaus AH, Kainberger F, et al. Bone erosions and bone marrow edema
as  deﬁned by magnetic resonance imaging reﬂect true bone marrow inﬂam-
mation in rheumatoid arthritis. Arthritis Rheum 2007;56(4):1118–24.
[4] Schett G. Bone marrow edema. Ann N Y Acad Sci 2009;1154:35–40.
[5] Helenius LM,  Tervahartiala P, Helenius I, Al-Sukhun J, Kivisaari L, Suuronen
R,  et al. Clinical, radiographic and MRI  ﬁndings of the temporomandibular
joint in patients with different rheumatic diseases. Int J Oral Maxillofac Surg
2006;35(11):983–9.
[6] Narvaez JA, Narvaez J, Aguilera C, De Lama E, Portabella F. MR imaging of
synovial tumors and tumor-like lesions. Eur Radiol 2001;11(12):2549–60.
[7] Colebatch AN, Edwards CJ, Ostergaard M,  van der Heijde D, Balint PV,
D’Agostino MA,  et al. EULAR recommendations for the use of imaging of the
joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis
2013;72(6):804–14.
[8] Schett G, David JP. The multiple faces of autoimmune-mediated bone loss.
Nat Rev Endocrinol 2010;6(12):698–706.
[9] Jin Z, Li X, Wan  Y. Minireview: nuclear receptor regulation of osteoclast and
bone remodeling. Mol Endocrinol 2015;29(2):172–86.
[10] Boyce BF. Advances in the regulation of osteoclasts and osteoclast functions.
J  Dent Res 2013;92(10):860–7.
[11] Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between
the immune and bone systems. Nat Rev Immunol 2007;7(4):292–304.
[12] Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and
function. Nat Rev Genet 2003;4(8):638–49.ience Review 55 (2019) 12–19 17
[13] Tsurukai T, Udagawa N, Matsuzaki K, Takahashi N, Suda T. Roles of
macrophage-colony stimulating factor and osteoclast differentiation factor
in  osteoclastogenesis. J Bone Miner Metab 2000;18(4):177–84.
[14] Boyce BF. Advances in osteoclast biology reveal potential new drug targets
and new roles for osteoclasts. J Bone Miner Res 2013;28(4):711–22.
[15] Snider AJ. Sphingosine kinase and sphingosine-1-phosphate: regulators in
autoimmune and inﬂammatory disease. Int J Clin Rheumtol 2013;8(4).
[16] Pi X, Tan SY, Hayes M,  Xiao L, Shayman JA, Ling S, et al. Sphingosine kinase
1-mediated inhibition of Fas death signaling in rheumatoid arthritis B lym-
phoblastoid cells. Arthritis Rheum 2006;54(3):754–64.
[17] Wu X, McKenna MA,  Feng X, Nagy TR, McDonald JM.  Osteoclast apoptosis:
the role of Fas in vivo and in vitro. Endocrinology 2003;144(12):5545–55.
[18] Kitano M,  Hla T, Sekiguchi M,  Kawahito Y, Yoshimura R, Miyazawa K, et al.
Sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling in
rheumatoid synovium: regulation of synovial proliferation and inﬂammatory
gene expression. Arthritis Rheum 2006;54(3):742–53.
[19] Takeshita H, Kitano M, Iwasaki T, Kitano S, Tsunemi S, Sato C, et al. Sphingo-
sine 1-phosphate (S1P)/S1P receptor 1 signaling regulates receptor activator
of  NF-kappaB ligand (RANKL) expression in rheumatoid arthritis. Biochem
Biophys Res Commun 2012;419(2):154–9.
[20] Spiegel S, Milstien S. Exogenous and intracellularly generated sphingosine 1-
phosphate can regulate cellular processes by divergent pathways. Biochem
Soc Trans 2003;31(Pt 6):1216–9.
[21] Ishii M,  Egen JG, Klauschen F, Meier-Schellersheim M,  Saeki Y, Vacher J, et al.
Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone
homeostasis. Nature 2009;458(7237):524–8.
[22] Ryu J, Kim HJ, Chang EJ, Huang H, Banno Y, Kim HH. Sphingosine 1-phosphate
as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling.
EMBO J 2006;25(24):5840–51.
[23] Kikuta J, Kawamura S, Okiji F, Shirazaki M,  Sakai S, Saito H, et al. Sphingosine-
1-phosphate-mediated osteoclast precursor monocyte migration is a critical
point of control in antibone-resorptive action of active vitamin D. Proc Natl
Acad  Sci U S A 2013;110(17):7009–13.
[24] Feng X. RANKing intracellular signaling in osteoclasts. IUBMB Life
2005;57(6):389–95.
[25] Wu X, Pan G, McKenna MA, Zayzafoon M,  Xiong WC,  McDonald JM.  RANKL
regulates Fas expression and Fas-mediated apoptosis in osteoclasts. J Bone
Miner Res 2005;20(1):107–16.
[26] Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF. Estrogen pro-
motes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med
1996;2(10):1132–6.
[27] Kameda T, Mano H,  Yuasa T, Mori Y, Miyazawa K, Shiokawa M,  et al. Estrogen
inhibits bone resorption by directly inducing apoptosis of the bone-resorbing
osteoclasts. J Exp Med  1997;186(4):489–95.
[28] Yoneda T, Ishimaru N, Arakaki R, Kobayashi M,  Izawa T, Moriyama K, et al.
Estrogen deﬁciency accelerates murine autoimmune arthritis associated with
receptor activator of nuclear factor-kappa B ligand-mediated osteoclastoge-
nesis. Endocrinology 2004;145(5):2384–91.
[29] Arnett TR, Lindsay R, Kilb JM,  Moonga BS, Spowage M, Dempster DW.  Selec-
tive toxic effects of tamoxifen on osteoclasts: comparison with the effects of
oestrogen. J Endocrinol 1996;149(3):503–8.
[30] Halasy-Nagy JM,  Rodan GA, Reszka AA. Inhibition of bone resorption by
alendronate and risedronate does not require osteoclast apoptosis. Bone
2001;29(6):553–9.
[31] Suzuki A, Iwata J. Mouse genetic models for temporomandibular joint devel-
opment and disorders. Oral Dis 2016;22(1):33–8.
[32] Tanaka E, Detamore MS,  Mercuri LG. Degenerative disorders of the tem-
poromandibular joint: etiology, diagnosis, and treatment. J Dent Res
2008;87(4):296–307.
[33] Benjamin M,  Ralphs JR. Biology of ﬁbrocartilage cells. Int Rev Cytol
2004;233:1–45.
[34] Hinton RJ, Serrano M,  So S. Differential gene expression in the perichon-
drium and cartilage of the neonatal mouse temporomandibular joint. Orthod
Craniofac Res 2009;12(3):168–77.
[35] Shen G, Darendeliler MA.  The adaptive remodeling of condylar cartilage—a
transition from chondrogenesis to osteogenesis. J Dent Res 2005;84(8):691–9.
[36] Ogus H. Rheumatoid arthritis of the temporomandibular joint. Br J Oral Surg
1975;12(3):275–84.
[37] Goupille P, Fouquet B, Goga D, Cotty P, Valat JP. The temporomandibular
joint in rheumatoid arthritis: correlations between clinical and tomographic
features. J Dent 1993;21(3):141–6.
[38] Hajati AK, Alstergren P, Nasstrom K, Bratt J, Kopp S. Endogenous glutamate in
association with inﬂammatory and hormonal factors modulates bone tissue
resorption of the temporomandibular joint in patients with early rheumatoid
arthritis. J Oral Maxillofac Surg 2009;67(9):1895–903.
[39] Delantoni A, Spyropoulou E, Chatzigiannis J, Papademitriou P. Sole radio-
graphic expression of rheumatoid arthritis in the temporomandibular
joints: a case report. Oral Surg Oral Med  Oral Pathol Oral Radiol Endod
2006;102(4):e37–40.
[40] Lin YC, Hsu ML,  Yang JS, Liang TH, Chou SL, Lin HY. Temporomandibu-
lar joint disorders in patients with rheumatoid arthritis. J Chin Med  Assoc
2007;70(12):527–34.
[41] Sodhi A, Naik S, Pai A, Anuradha A. Rheumatoid arthritis affecting temporo-
mandibular joint. Contemp Clin Dent 2015;6(1):124–7.
[42] Gleissner C, Kaesser U, Dehne F, Bolten WW,  Willershausen B. Temporo-
mandibular joint function in patients with longstanding rheumatoid arthritis
1 tal Sc8 I.R. Hutami et al. / Japanese Den
− I. Role of periodontal status and prosthetic care — a clinical study. Eur J Med
Res 2003;8(3):98–108.
[43] Narvaez JA, Narvaez J, Roca Y, Aguilera C. MR imaging assessment of clinical
problems in rheumatoid arthritis. Eur Radiol 2002;12(7):1819–28.
[44] Ruparelia PB, Shah DS, Ruparelia K, Sutaria SP, Pathak D. Bilateral TMJ Involve-
ment in Rheumatoid Arthritis. Case Rep Dent 2014;2014:262430.
[45] Gynther GW,  Holmlund AB, Reinholt FP, Lindblad S. Temporomandibular joint
involvement in generalized osteoarthritis and rheumatoid arthritis: a clinical,
arthroscopic, histologic, and immunohistochemical study. Int J Oral Maxillo-
fac  Surg 1997;26(1):10–6.
[46] Ghassemi-Nejad S, Kobezda T, Rauch TA, Matesz C, Glant TT, Mikecz K.
Osteoarthritis-like damage of cartilage in the temporomandibular joints
in  mice with autoimmune inﬂammatory arthritis. Osteoarthritis Cartilage
2011;19(4):458–65.
[47] Liu WW,  Xu ZM,  Li ZQ, Zhang Y, Han B. RANKL, OPG and CTR mRNA expres-
sion in the temporomandibular joint in rheumatoid arthritis. Exp Ther Med
2015;10(3):895–900.
[48] Ueno T, Kagawa T, Kanou M,  Ishida N, Fujii T, Fukunaga J, et al. Pathology of the
temporomandibular joint of patients with rheumatoid arthritis—case reports
of  secondary amyloidosis and macrophage populations. J Craniomaxillofac
Surg 2003;31(4):252–6.
[49] Moen K, Bertelsen LT, Hellem S, Jonsson R, Brun JG. Salivary gland and tem-
poromandibular joint involvement in rheumatoid arthritis: relation to disease
activity. Oral Dis 2005;11(1):27–34.
[50] Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lym-
phoproliferation disorder in mice explained by defects in Fas antigen that
mediates apoptosis. Nature 1992;356(6367):314–7.
[51] Palao G, Santiago B, Galindo M,  Paya M, Ramirez JC, Pablos JL. Down-regulation
of  FLIP sensitizes rheumatoid synovial ﬁbroblasts to Fas-mediated apoptosis.
Arthritis Rheum 2004;50(9):2803–10.
[52] Watanabe T, Sakai Y, Miyawaki S, Shimizu A, Koiwai O, Ohno K. A molecular
genetic linkage map  of mouse chromosome 19, including the lpr, Ly-44, and
Tdt genes. Biochem Genet 1991;29(7-8):325–35.
[53] Watson ML, Rao JK, Gilkeson GS, Ruiz P, Eicher EM, Pisetsky DS, et al.
Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene
to disease manifestations and renal disease-modifying loci. J Exp Med
1992;176(6):1645–56.
[54] Adachi M,  Watanabe-Fukunaga R, Nagata S. Aberrant transcription caused by
the insertion of an early transposable element in an intron of the Fas antigen
gene of lpr mice. Proc Natl Acad Sci U S A 1993;90(5):1756–60.
[55] Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoim-
munity and lymphoproliferative disease. Annu Rev Immunol 1991;9:243–69.
[56] Ootsuyama A, Okazaki R, Norimura T. Effect of extended exposure to low-
dose radiation on autoimmune diseases of immunologically suppressed
MRL/MpTn-gld/gld mice. J Radiat Res 2003;44(3):243–7.
[57] Hou LF, He SJ, Li X, Yang Y, He PL, Zhou Y, et al. Oral administration of
artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by
inhibiting Th1 and Th17 cell responses. Arthritis Rheum 2011;63(8):2445–55.
[58] Takahashi S, Futatsugi-Yumikura S, Fukuoka A, Yoshimoto T, Nakanishi K,
Yonehara S. Fas deﬁciency in mice with the Balb/c background induces ble-
pharitis with allergic inﬂammation and hyper-IgE production in conjunction
with severe autoimmune disease. Int Immunol 2013;25(5):287–93.
[59] Chu JL, Ramos P, Rosendorff A, Nikolic-Zugic J, Lacy E, Matsuzawa A, et al.
Massive upregulation of the Fas ligand in lpr and gld mice: implications for
Fas regulation and the graft-versus-host disease-like wasting syndrome. J Exp
Med  1995;181(1):393–8.
[60] Haraldson T, Jonsson R, Tarkowski A. Spontaneous temporomandibular joint
arthropathy in MRL-lpr/lpr mice. J Oral Pathol 1988;17(8):386–9.
[61] Ratkay LG, Tait B, Tonzetich J, Waterﬁeld JD. Lpr and MRL  background gene
involvement in the control of adjuvant enhanced arthritis in MRL-lpr mice. J
Autoimmun 1994;7(5):561–73.
[62] Izawa T, Ishimaru N, Moriyama K, Kohashi M,  Arakaki R, Hayashi Y. Crosstalk
between RANKL and Fas signaling in dendritic cells controls immune toler-
ance. Blood 2007;110(1):242–50.
[63] Izawa T, Kondo T, Kurosawa M,  Oura R, Matsumoto K, Tanaka E, et al. Fas-
independent T-cell apoptosis by dendritic cells controls autoimmune arthritis
in  MRL/lpr mice. PLoS One 2012;7(12):1–12, e48798.
[64] Liu W,  Xu C, Zhao H, Xia P, Song R, Gu J, et al. Osteoprotegerin induces apopto-
sis of osteoclasts and osteoclast precursor cells via the Fas/Fas ligand pathway.
PLoS One 2015;10(11):1–14, e0142519.
[65] Hutami IR, Izawa T, Mino-Oka A, Shinohara T, Mori H, Iwasa A, et al.
Fas/S1P1 crosstalk via NF-kappaB activation in osteoclasts controls subchon-
dral bone remodeling in murine TMJ  arthritis. Biochem Biophys Res Commun
2017;490(4):1274–81.
[66] Hla T. Physiological and pathological actions of sphingosine 1-phosphate.
Semin Cell Dev Biol 2004;15(5):513–20.
[67] Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in
immunity. Nat Rev Immunol 2011;11(6):403–15.
[68] Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid.
Nat  Rev Mol  Cell Biol 2003;4(5):397–407.
[69] Schwab SR, Cyster JG. Finding a way  out: lymphocyte egress from lymphoid
organs. Nat Immunol 2007;8(12):1295–301.
[70] Cuvillier O. Sphingosine in apoptosis signaling. Biochim Biophys Acta
2002;1585(2-3):153–62.ience Review 55 (2019) 12–19
[71] Kluk MJ,  Hla T. Signaling of sphingosine-1-phosphate via the S1P/EDG-family
of  G-protein-coupled receptors. Biochim Biophys Acta 2002;1582(1-
3):72–80.
[72] Takabe K, Paugh SW,  Milstien S, Spiegel S. “Inside-out” signal-
ing of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev
2008;60(2):181–95.
[73] Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J
Cell Biochem 2004;92(5):913–22.
[74] Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G,  Hoyer D, et al. Brain
sphingosine-1-phosphate receptors: implication for FTY720 in the treatment
of multiple sclerosis. Pharmacol Ther 2008;117(1):77–93.
[75] Jovanovic DV, Martel-Pelletier J, Di Battista JA, Mineau F, Jolicoeur FC, Bender-
dour M,  et al. Stimulation of 92-kd gelatinase (matrix metalloproteinase 9)
production by interleukin-17 in human monocyte/macrophages: a possible
role in rheumatoid arthritis. Arthritis Rheum 2000;43(5):1134–44.
[76] Quint P, Ruan M, Pederson L, Kassem M,  Westendorf JJ, Khosla S, et al. Sphingo-
sine 1-phosphate (S1P) receptors 1 and 2 coordinately induce mesenchymal
cell  migration through S1P activation of complementary kinase pathways. J
Biol Chem 2013;288(8):5398–406.
[77] Goetzl EJ, Rosen H. Regulation of immunity by lysosphingolipids and their G
protein-coupled receptors. J Clin Invest 2004;114(11):1531–7.
[78] Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine
and  paracrine network. Nat Rev Immunol 2005;5(7):560–70.
[79] Pettus BJ, Bielawski J, Porcelli AM,  Reames DL, Johnson KR, Morrow J,
et al. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates
COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J
2003;17(11):1411–21.
[80] Lotinun S, Kiviranta R, Matsubara T, Alzate JA, Neff L, Luth A, et al. Osteoclast-
speciﬁc cathepsin K deletion stimulates S1P-dependent bone formation. J Clin
Invest 2013;123(2):666–81.
[81] Brizuela L, Martin C, Jeannot P, Ader I, Gstalder C, Andrieu G,  et al.
Osteoblast-derived sphingosine 1-phosphate to induce proliferation and con-
fer  resistance to therapeutics to bone metastasis-derived prostate cancer
cells. Mol  Oncol 2014;8(7):1181–95.
[82] Mori H, Izawa T, Tanaka E. Smad3 deﬁciency leads to mandibular condyle
degradation via the sphingosine 1-phosphate (S1P)/S1P3 signaling axis. Am J
Pathol 2015;185(10):2742–56.
[83] Ishii T, Shimazu Y, Nishiyama I, Kikuta J, Ishii M.  The role of sphingosine 1-
phosphate in migration of osteoclast precursors; an application of intravital
two-photon microscopy. Mol  Cells 2011;31(5):399–403.
[84] Xiao L, Zhou Y, Zhu L, Yang S, Huang R, Shi W,  et al. SPHK1-S1PR1-RANKL axis
regulates the interactions between macrophages and BMSCs in inﬂammatory
bone loss. J Bone Miner Res 2018.
[85] Kikuta J, Iwai K, Saeki Y, Ishii M.  S1P-targeted therapy for elderly rheumatoid
arthritis patients with osteoporosis. Rheumatol Int 2011;31(7):967–9.
[86] Price ST, Beckham TH, Cheng JC, Lu P, Liu X, Norris JS. Sphingosine 1-Phosphate
receptor 2 regulates the migration, proliferation, and differentiation of mes-
enchymal stem Cells. Int J Stem Cell Res Ther 2015;2(2):1–14.
[87] Zhao C, Fernandes MJ,  Turgeon M,  Tancrede S, Di Battista J, Poubelle PE,
et al. Speciﬁc and overlapping sphingosine-1-phosphate receptor functions in
human synoviocytes: impact of TNF-alpha. J Lipid Res 2008;49(11):2323–37.
[88] Jimi E, Aoki K, Saito H, D’Acquisto F, May  MJ,  Nakamura I, et al. Selective inhi-
bition of NF-kappa B blocks osteoclastogenesis and prevents inﬂammatory
bone destruction in vivo. Nat Med  2004;10(6):617–24.
[89] Jones DH, Kong YY, Penninger JM.  Role of RANKL and RANK in bone loss and
arthritis. Ann Rheum Dis 2002;61(Suppl. 2):ii32–9.
[90] Brown KD, Claudio E, Siebenlist U. The roles of the classical and alternative
nuclear factor-kappaB pathways: potential implications for autoimmunity
and rheumatoid arthritis. Arthritis Res Ther 2008;10(4):212.
[91] Xing L, Schwarz EM,  Boyce BF. Osteoclast precursors, RANKL/RANK, and
immunology. Immunol Rev 2005;208:19–29.
[92] Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice
lacking NF-kappaB1 and NF-kappaB2. Nat Med  1997;3(11):1285–9.
[93] Franzoso G, Carlson L, Xing L, Poljak L, Shores EW,  Brown KD, et al.
Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev
1997;11(24):3482–96.
[94] Spehlmann ME,  Eckmann L. Nuclear factor-kappa B in intestinal protection
and destruction. Curr Opin Gastroenterol 2009;25(2):92–9.
[95] Ghosh S, Karin M.  Missing pieces in the NF-kappaB puzzle. Cell
2002;109(Suppl):S81–96.
[96] Karin M, Yamamoto Y, Wang QM.  The IKK NF-kappa B system: a treasure trove
for  drug development. Nat Rev Drug Discov 2004;3(1):17–26.
[97] Karin M,  Delhase M.  The I kappa B kinase (IKK) and NF-kappa B: key elements
of  proinﬂammatory signalling. Semin Immunol 2000;12(1):85–98.
[98] Novack DV. Role of NF-kappaB in the skeleton. Cell Res 2011;21(1):169–82.
[99] Oura R, Arakaki R, Yamada A, Kudo Y, Tanaka E, Hayashi Y, et al. Induction of
rapid T cell death and phagocytic activity by Fas-deﬁcient lpr macrophages. J
Immunol 2013;190(2):578–85.
[100] Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF-kappaB acti-
vation by small molecules as a therapeutic strategy. Biochim Biophys Acta
2010;1799(10–12):775–87.[101] Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A, Ben-Neriah Y.
Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa
B  inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl
Acad Sci U S A 1995;92(23):10599–603.
tal Sc
[
[
[
[
cyte/macrophage lineage precursor cells. Bone 2011;48(6):1336–45.
[108] Kolenko V, Bloom T, Rayman P, Bukowski R, Hsi E, Finke J. Inhibition of
NF-kappa B activity in human T lymphocytes induces caspase-dependent
apoptosis without detectable activation of caspase-1 and -3. J Immunol
1999;163(2):590–8.I.R. Hutami et al. / Japanese Den
102] Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear
translocation of transcription factor NF-kappa B by a synthetic peptide con-
taining a cell membrane-permeable motif and nuclear localization sequence.
J  Biol Chem 1995;270(24):14255–8.
103] Tan X, Wen  X, Liu Y. Paricalcitol inhibits renal inﬂammation by promoting
vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc
Nephrol 2008;19(9):1741–52.
104] Salmond RJ, Pitman RS, Jimi E, Soriani M,  Hirst TR, Ghosh S, et al. CD8+ T cell
apoptosis induced by Escherichia coli heat-labile enterotoxin B subunit occurs
via a novel pathway involving NF-kappaB-dependent caspase activation. Eur
J  Immunol 2002;32(6):1737–47.
105] Saika S, Miyamoto T, Yamanaka O, Kato T, Ohnishi Y, Flanders KC, et al.
Therapeutic effect of topical administration of SN50, an inhibitor of nuclear
factor-kappaB, in treatment of corneal alkali burns in mice. Am J Pathol
2005;166(5):1393–403.ience Review 55 (2019) 12–19 19
[106] Yoshida M, Korfhagen TR, Whitsett JA. Surfactant protein D regulates NF-
kappa B and matrix metalloproteinase production in alveolar macrophages
via  oxidant-sensitive pathways. J Immunol 2001;166(12):7514–9.
[107] Wang YM, Lu TL, Hsu PN, Tang CH, Chen JH, Liu KC, et al. Ribosome
inactivating protein B-chain induces osteoclast differentiation from mono-
